6-Hydroxytryptamine

6-Hydroxytryptamine shows dramatically reduced affinity for serotonin receptors, including the serotonin 5-HT_1A, 5-HT_1B, 5-HT_2A, and 5-HT_2C receptors (K_i = 1,590 nM, 5,890 nM, 11,500 nM, and 5,500 nM, respectively), compared to serotonin, 4-hydroxytryptamine, 5-methoxytryptamine, and certain other tryptamines.^[3] It did not produce hyperlocomotion in rodents but did partially reverse reserpine-induced hypoactivity.^[4] 6-Hydroxytryptamine appears to be less susceptible to metabolism by monoamine oxidase (MAO) than serotonin.^[5]

6-Hydroxytryptamine was first described in the scientific literature by the 1950s.^[6]

Certain β-carbolines and harmala alkaloids, such as harmol, harmalol, and tetrahydroharmol, as well as their O-methyl (methoxy) analogues including harmine, harmaline, and tetrahydroharmine, are notable in being naturally occurring cyclized tryptamine derivatives of 6-hydroxytryptamine.^[7][8] The same is true of certain iboga alkaloids, such as tabernanthine and ibogaline.^{[9][10][11][12]} Tabernanthalog (DLX-007) is a synthetic simplified ibogalog analogue of tabernanthine that is under development for use as a potential pharmaceutical drug in the treatment of neuropsychiatric disorders.^[13][14]

• Substituted tryptamine
• 4-Hydroxytryptamine
• 6-Methoxytryptamine
• 6-Hydroxy-DMT
• 6-MeO-DMT
• 5-MeO-isoDMT
• Zalsupindole (DLX-001, AAZ-A-154)